vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and MERCURY GENERAL CORP (MCY). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $1.5B, roughly 1.8× MERCURY GENERAL CORP). MERCURY GENERAL CORP runs the higher net margin — 13.2% vs -3.7%, a 16.9% gap on every dollar of revenue. On growth, MERCURY GENERAL CORP posted the faster year-over-year revenue change (12.4% vs 9.3%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $273.9M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs 9.8%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Mercury General Corporation is a multiple-line insurance organization that offers personal automobiles, homeowners, renters, and business insurance. Mercury's primary focus is automobiles and homeowners' insurance.
BHC vs MCY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $1.5B |
| Net Profit | $-103.0M | $202.5M |
| Gross Margin | — | 99.7% |
| Operating Margin | 17.0% | 16.2% |
| Net Margin | -3.7% | 13.2% |
| Revenue YoY | 9.3% | 12.4% |
| Net Profit YoY | -205.1% | 100.4% |
| EPS (diluted) | $-0.30 | $3.66 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $1.5B | ||
| Q3 25 | $2.7B | $1.6B | ||
| Q2 25 | $2.5B | $1.5B | ||
| Q1 25 | $2.3B | $1.4B | ||
| Q4 24 | $2.6B | $1.4B | ||
| Q3 24 | $2.5B | $1.5B | ||
| Q2 24 | $2.4B | $1.3B | ||
| Q1 24 | $2.2B | $1.3B |
| Q4 25 | $-103.0M | $202.5M | ||
| Q3 25 | $179.0M | $280.4M | ||
| Q2 25 | $148.0M | $166.5M | ||
| Q1 25 | $-58.0M | $-108.3M | ||
| Q4 24 | $98.0M | $101.1M | ||
| Q3 24 | $-85.0M | $230.9M | ||
| Q2 24 | $10.0M | $62.6M | ||
| Q1 24 | $-64.0M | $73.5M |
| Q4 25 | — | 99.7% | ||
| Q3 25 | — | 99.8% | ||
| Q2 25 | — | 99.8% | ||
| Q1 25 | — | 99.7% | ||
| Q4 24 | — | 99.7% | ||
| Q3 24 | — | 99.8% | ||
| Q2 24 | — | 99.8% | ||
| Q1 24 | — | 99.7% |
| Q4 25 | 17.0% | 16.2% | ||
| Q3 25 | 23.1% | 22.1% | ||
| Q2 25 | 17.5% | 14.0% | ||
| Q1 25 | 12.2% | -10.2% | ||
| Q4 24 | 21.8% | 9.0% | ||
| Q3 24 | 12.7% | 18.8% | ||
| Q2 24 | 16.2% | 5.8% | ||
| Q1 24 | 13.1% | 7.0% |
| Q4 25 | -3.7% | 13.2% | ||
| Q3 25 | 6.7% | 17.7% | ||
| Q2 25 | 5.8% | 11.3% | ||
| Q1 25 | -2.6% | -7.8% | ||
| Q4 24 | 3.8% | 7.4% | ||
| Q3 24 | -3.4% | 15.1% | ||
| Q2 24 | 0.4% | 4.8% | ||
| Q1 24 | -3.0% | 5.8% |
| Q4 25 | $-0.30 | $3.66 | ||
| Q3 25 | $0.48 | $5.06 | ||
| Q2 25 | $0.40 | $3.01 | ||
| Q1 25 | $-0.16 | $-1.96 | ||
| Q4 24 | $0.24 | $1.82 | ||
| Q3 24 | $-0.23 | $4.17 | ||
| Q2 24 | $0.03 | $1.13 | ||
| Q1 24 | $-0.17 | $1.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | — |
| Total DebtLower is stronger | $20.8B | $575.0M |
| Stockholders' EquityBook value | $-554.0M | $2.4B |
| Total Assets | $26.4B | $9.6B |
| Debt / EquityLower = less leverage | — | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $719.0M | — | ||
| Q2 24 | $595.0M | — | ||
| Q1 24 | $733.0M | — |
| Q4 25 | $20.8B | $575.0M | ||
| Q3 25 | $21.0B | — | ||
| Q2 25 | $21.7B | — | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.6B | $575.0M | ||
| Q3 24 | $21.5B | — | ||
| Q2 24 | $21.7B | — | ||
| Q1 24 | $22.1B | — |
| Q4 25 | $-554.0M | $2.4B | ||
| Q3 25 | $-565.0M | $2.2B | ||
| Q2 25 | $-764.0M | $2.0B | ||
| Q1 25 | $-1.2B | $1.8B | ||
| Q4 24 | $-1.3B | $1.9B | ||
| Q3 24 | $-1.2B | $1.9B | ||
| Q2 24 | $-1.2B | $1.6B | ||
| Q1 24 | $-1.1B | $1.6B |
| Q4 25 | $26.4B | $9.6B | ||
| Q3 25 | $26.8B | $9.4B | ||
| Q2 25 | $27.3B | $9.1B | ||
| Q1 25 | $26.4B | $9.0B | ||
| Q4 24 | $26.5B | $8.3B | ||
| Q3 24 | $26.5B | $8.2B | ||
| Q2 24 | $26.5B | $7.7B | ||
| Q1 24 | $26.9B | $7.4B |
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $287.9M |
| Free Cash FlowOCF − Capex | $403.0M | $273.9M |
| FCF MarginFCF / Revenue | 14.4% | 17.8% |
| Capex IntensityCapex / Revenue | 3.3% | 0.9% |
| Cash ConversionOCF / Net Profit | — | 1.42× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $287.9M | ||
| Q3 25 | $405.0M | $496.4M | ||
| Q2 25 | $289.0M | $371.6M | ||
| Q1 25 | $211.0M | $-68.7M | ||
| Q4 24 | $601.0M | $248.3M | ||
| Q3 24 | $405.0M | $318.1M | ||
| Q2 24 | $380.0M | $278.0M | ||
| Q1 24 | $211.0M | $192.6M |
| Q4 25 | $403.0M | $273.9M | ||
| Q3 25 | $314.0M | $479.5M | ||
| Q2 25 | $190.0M | $357.2M | ||
| Q1 25 | $96.0M | $-81.9M | ||
| Q4 24 | $495.0M | $236.0M | ||
| Q3 24 | $334.0M | $306.2M | ||
| Q2 24 | $302.0M | $266.5M | ||
| Q1 24 | $129.0M | $182.4M |
| Q4 25 | 14.4% | 17.8% | ||
| Q3 25 | 11.7% | 30.3% | ||
| Q2 25 | 7.5% | 24.2% | ||
| Q1 25 | 4.2% | -5.9% | ||
| Q4 24 | 19.3% | 17.3% | ||
| Q3 24 | 13.3% | 20.0% | ||
| Q2 24 | 12.6% | 20.4% | ||
| Q1 24 | 6.0% | 14.3% |
| Q4 25 | 3.3% | 0.9% | ||
| Q3 25 | 3.4% | 1.1% | ||
| Q2 25 | 3.9% | 1.0% | ||
| Q1 25 | 5.1% | 0.9% | ||
| Q4 24 | 4.1% | 0.9% | ||
| Q3 24 | 2.8% | 0.8% | ||
| Q2 24 | 3.2% | 0.9% | ||
| Q1 24 | 3.8% | 0.8% |
| Q4 25 | — | 1.42× | ||
| Q3 25 | 2.26× | 1.77× | ||
| Q2 25 | 1.95× | 2.23× | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.13× | 2.46× | ||
| Q3 24 | — | 1.38× | ||
| Q2 24 | 38.00× | 4.44× | ||
| Q1 24 | — | 2.62× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
MCY
Segment breakdown not available.
